Steering Group Meeting – February 2019, London, UK

The Project HERCULES Steering Group is the decision-making body which oversees the delivery of the objectives of Project HERCULES. The group meets quarterly and is chaired by Fleur Chandler.

Access to Project HERCULES Steering Group content is restricted to Steering Group members only.

Project HERCULES team

Members include:

  • Fleur Chandler (Chair), Duchenne UK and Alcmena Consulting Ltd
  • Emily Crossley, Duchenne UK
  • Josie Godfrey, JG Zebra Consulting
  • Bally Sappal, JG Zebra Consulting

Companies

Members include representatives from:

  • Catabasis Pharmaceuticals Inc
  • Pfizer Inc
  • PTC Therapeutics International Limited,
  • Roche
  • Sarepta Therapeutics Inc
  • Solid Biosciences LLC
  • Santhera Pharmaceuticals Holding AG
  • Wave Life Sciences USA

Patient groups

Members include representatives from:

  • PPMD (US)
  • World Duchenne Organisation (UPPMD)
  • Save Our Sons (Australia)
  • Stand for Duchenne Canada

Advisers

  • Prof Ron Akehurst, BresMed
  • Meriem Bouslouk, Independent German HTA expert
  • Merce Obach Cortadellas, Catsalut
  • Carla Deakin, NICE
  • Prof Jalpa Doshi, University of Pennsylvania
  • Karen Facey, University of Edinburgh
  • Dr Michela Guglieri, Newcastle University
  • Anthony Hatswell, Delta Hat
  • Jane Larkindale, C-Path (US)
  • Dr Anna Sarkozy, GOSH London
  • Juliana Setyawan, US
  • James Signorovitch and Susan Ward, cTAP (US)    

Vendors

Vendors also attend the Steering Group:

  • Aparito
  • HCD Economics
  • Sheffield School of Health and Related Research (ScHARR)
  • Source HEOR
  • University of Leicester